Krebs Biochemicals reports Q4 & FY26 results; net loss narrows
Krebs Biochemicals & Industries Limited declared its audited financial results for Q4 and FY26 ending March 31, 2026. The company reported a loss before tax of ₹233.96 lacs for the quarter and ₹1693.31 lacs for the year. The statutory auditors issued an unmodified report.
The announcement pertains to the company's audited financial results, which are material information for investors. While the results show continued losses, the unmodified audit report and the clear disclosure of financial performance have a medium impact on stakeholders.
The company reported a net loss for both the quarter and the full financial year, which is a negative indicator. However, the auditors issued an unmodified report, which is a neutral to positive sign. The overall sentiment is neutral due to the continued losses.
Krebs Biochemicals and Industries Limited announced its audited financial results for the fourth quarter and the financial year ended March 31, 2026. The Board of Directors, in their meeting held on May 21, 2026, approved and took on record these results. The meeting commenced at 11:30 am and concluded at 1:20 pm.
For the fourth quarter ended March 31, 2026, the company reported total income of ₹881.27 lacs and total expenses of ₹1115.23 lacs, resulting in a loss before tax of ₹233.96 lacs. For the full financial year ended March 31, 2026, total income stood at ₹4402.08 lacs, while total expenses were ₹7094.48 lacs, leading to a loss before tax of ₹1693.31 lacs. The net loss for the quarter was ₹233.96 lacs, and for the financial year it was ₹1693.31 lacs. The company reported an 'Unmodified Report' from its statutory auditors, Bhavani & Co.
The company's Visakhapatnam manufacturing unit remains closed following an order from the Andhra Pradesh Pollution Control Board on February 7, 2025. Krebs Biochemicals is actively engaged in discussions with the board for the revocation of this closure order. The company also stated that its current wage structure is aligned with new Labour Codes, and no material incremental liability is expected for gratuity, leave encashment, and other obligations.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.